[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008029237A3 - Polythérapies destinées au traitement de l'arthrite rhumatoïde - Google Patents

Polythérapies destinées au traitement de l'arthrite rhumatoïde Download PDF

Info

Publication number
WO2008029237A3
WO2008029237A3 PCT/IB2007/002468 IB2007002468W WO2008029237A3 WO 2008029237 A3 WO2008029237 A3 WO 2008029237A3 IB 2007002468 W IB2007002468 W IB 2007002468W WO 2008029237 A3 WO2008029237 A3 WO 2008029237A3
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatoid arthritis
pharmaceutically acceptable
acceptable salt
combination therapies
human
Prior art date
Application number
PCT/IB2007/002468
Other languages
English (en)
Other versions
WO2008029237A2 (fr
Inventor
Paul Steven Changelian
Samuel Hyman Zwillich
Original Assignee
Pfizer Prod Inc
Paul Steven Changelian
Samuel Hyman Zwillich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Paul Steven Changelian, Samuel Hyman Zwillich filed Critical Pfizer Prod Inc
Publication of WO2008029237A2 publication Critical patent/WO2008029237A2/fr
Publication of WO2008029237A3 publication Critical patent/WO2008029237A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des polythérapies destinées au traitement ou à la prévention de l'arthrite chez un humain, telle que l'arthrite rhumatoïde. Lesdites polythérapies comprennent un inhibiteur de la Janus Kinase ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un agent anti-arthritique ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également certains procédés destinés au traitement ou à la prévention de l'arthrite chez un humain, telle que l'arthrite rhumatoïde. Lesdits procédés comprennent l'administration combinée, à un humain, d'un inhibiteur de la Janus Kinase ou d'un sel pharmaceutiquement acceptable de celui-ci, et d'au moins un agent anti-arthritique ou d'un sel pharmaceutiquement acceptable de celui-ci.
PCT/IB2007/002468 2006-09-05 2007-08-24 Polythérapies destinées au traitement de l'arthrite rhumatoïde WO2008029237A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84270406P 2006-09-05 2006-09-05
US60/842,704 2006-09-05

Publications (2)

Publication Number Publication Date
WO2008029237A2 WO2008029237A2 (fr) 2008-03-13
WO2008029237A3 true WO2008029237A3 (fr) 2008-05-15

Family

ID=39047038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002468 WO2008029237A2 (fr) 2006-09-05 2007-08-24 Polythérapies destinées au traitement de l'arthrite rhumatoïde

Country Status (4)

Country Link
JP (1) JP2008069149A (fr)
AR (1) AR062658A1 (fr)
TW (1) TW200823216A (fr)
WO (1) WO2008029237A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130009577A (ko) * 2009-04-20 2013-01-23 오스펙스 파마슈티컬즈 엘엘씨 야누스 키나아제 3의 피페리딘 억제제
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
AR079984A1 (es) 2010-01-12 2012-03-07 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
BR112012019511A2 (pt) * 2010-02-05 2016-08-23 Pfizer compostos de pirrolo [2,3-d] pirimidina como inibidores de jak.
CN102875555A (zh) * 2012-09-27 2013-01-16 同济大学 一种JAK抑制剂Tofacitinib的合成方法
CN103819474A (zh) * 2013-11-04 2014-05-28 湖南华腾制药有限公司 一种托法替尼的制备方法
TR201904767T4 (tr) * 2013-12-09 2019-05-21 Unichem Lab Ltd (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamin hazırlanması için geliştirilmiş bir işlem.
EP3248980B1 (fr) * 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Inhibiteur de jak
CN105237463B (zh) * 2015-10-09 2017-10-10 刘卫国 一种(3r,4r)‑(1‑苄基‑4‑甲基哌啶‑3‑基)甲胺‑l‑二对甲苯甲酰酒石酸盐的制备方法
CN106146517B (zh) * 2016-06-20 2018-08-28 山东大学 一种枸橼酸托法替尼的合成方法
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
CN114835631B (zh) * 2021-02-01 2024-02-13 重庆恩联生物科技有限公司 顺式-1-苄基-4-甲基-3-甲氨基-哌啶双盐酸盐的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042246A2 (fr) * 1999-12-10 2001-06-14 Pfizer Products Inc. Composes a base de pyrrolo[2,3-d]pyrimidine
WO2005051393A1 (fr) * 2003-11-25 2005-06-09 Pfizer Products Inc. Methode de traitement de l'atherosclerose
EP1686130A1 (fr) * 2000-06-26 2006-08-02 Pfizer Products Incorporated Pyrrolo[2,3-d]pyrimidines comme agents immunosuppressifs.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042246A2 (fr) * 1999-12-10 2001-06-14 Pfizer Products Inc. Composes a base de pyrrolo[2,3-d]pyrimidine
EP1686130A1 (fr) * 2000-06-26 2006-08-02 Pfizer Products Incorporated Pyrrolo[2,3-d]pyrimidines comme agents immunosuppressifs.
WO2005051393A1 (fr) * 2003-11-25 2005-06-09 Pfizer Products Inc. Methode de traitement de l'atherosclerose

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "comparison of 6 CP-690550 doses vs placebo, each combined with methotrexate, for the treatment of rheumatoid arthritis", 18 December 2006 (2006-12-18), XP002469625, Retrieved from the Internet <URL:http://clinicaltrials.gov/show/NCT00413660> [retrieved on 20080218] *
ANONYMOUS: "extension study of stage 1 subjects of study A3921009 for the prevention of acute rejection in kidney transplant patient", CLINICALTRIALS.GOV, 6 December 2005 (2005-12-06), XP002469626, Retrieved from the Internet <URL:http://clinicaltrials.gov/show/NCT00263328> *
BORIE DOMINIC C ET AL: "Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates", TRANSPLANTATION (HAGERSTOWN), vol. 80, no. 12, December 2005 (2005-12-01), pages 1756 - 1764, XP009096259, ISSN: 0041-1337 *
CETKOVIC-CVRLJE M ET AL: "Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.", CURRENT PHARMACEUTICAL DESIGN 2004, vol. 10, no. 15, 2004, pages 1767 - 1784, XP009096151, ISSN: 1381-6128 *
DOAN TANYA ET AL: "Rheumatoid arthritis: An overview of new and emerging therapies", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 45, no. 7, July 2005 (2005-07-01), pages 751 - 762, XP009096292, ISSN: 0091-2700 *
GOLDBLUM R: "Therapy of rheumatoid arthritis with mycophenolate mofetil", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 1993 ITALY, vol. 11, no. SUPPL. 8, 1993, pages S117 - S119, XP009096173, ISSN: 0392-856X *
WALKER J G ET AL: "Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment", ANNALS OF THE RHEUMATIC DISEASES, vol. 65, no. 12, 7 June 2006 (2006-06-07), online, pages 1558 - 1564, XP009096143, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
JP2008069149A (ja) 2008-03-27
WO2008029237A2 (fr) 2008-03-13
TW200823216A (en) 2008-06-01
AR062658A1 (es) 2008-11-26

Similar Documents

Publication Publication Date Title
WO2008029237A3 (fr) Polythérapies destinées au traitement de l&#39;arthrite rhumatoïde
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2007087068A3 (fr) Inhibiteurs de tyrosine kinase et leurs utilisations
WO2006116148A3 (fr) Traitement de l&#39;abus de substances toxiques
WO2007146426A3 (fr) Nanobilles pour délivrance de médicament
WO2007146411A3 (fr) Thérapie basée sur des nanoparticules
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
WO2005023179A3 (fr) Methodes combinees de traitement du cancer
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
WO2006113498A3 (fr) 2-amino-quinazolin-5-ones
WO2004105737A3 (fr) Compositions pharmaceutiques et procedes pour inhiber les adherences fibreuses au moyen de differents agents
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2008049856A3 (fr) Procédés pour le traitement de la douleur
WO2007084424A3 (fr) Traitement de l&#39;abus de substances
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
EP2030615A3 (fr) Inhibiteurs de la ribonucleotide reductase pour leur utilisation dans le traitement ou la prévention de maladies neuro-inflammatoires ou auto-immunes
WO2006098979A3 (fr) Formes posologiques d&#39;aminopterine et methodes pour troubles inflammatoires
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu&#39;inhibiteurs de gsk-3
WO2006029036A3 (fr) Therapie combinee avec du glatiramere acetate et de la n-acetylcysteine pour traiter la sclerose en plaques
WO2007092469A3 (fr) Combinaison de composes organiques
WO2007120485A3 (fr) Procédés de traitement de la douleur avec des alkylxanthines et des antiépileptiques et compositions à utiliser à cet effet
MXPA04001397A (es) Metodo y composiciones para el tratamiento y prevencion de dolor e inflamacion con un inhibidor selectivo de cicloxigenasa-2 y sulfato de condroitina.
WO2006074265A3 (fr) Therapie combinee et compositions pharmaceutiques utilisees dans le traitement des troubles inflammatoires
WO2008016640A3 (fr) Traitement de l&#39;insuffisance cardiaque progressive chronique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789673

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07789673

Country of ref document: EP

Kind code of ref document: A2